Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
287 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Osteosarcoma - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H2 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape. Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 16, 4, 16 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 2 and 4 molecules, respectively. Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Osteosarcoma - Overview 7 Osteosarcoma - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 12 Products under Development by Companies 13 Products under Development by Universities/Institutes 16 Osteosarcoma - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 20 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Osteosarcoma - Companies Involved in Therapeutics Development 27 Advaxis Inc 27 Advenchen Laboratories LLC 27 Amgen Inc 28 AntiCancer Inc 28 Arrowhead Pharmaceuticals Inc 29 AVEO Pharmaceuticals Inc 29 Bayer AG 30 Bellicum Pharmaceuticals Inc 30 Boehringer Ingelheim GmbH 31 Bristol-Myers Squibb Company 31 Celldex Therapeutics Inc 32 Cellmid Ltd 32 CorMedix Inc 33 Daiichi Sankyo Company Ltd 33 Eisai Co Ltd 34 Eleison Pharmaceuticals LLC 34 Intezyne Technologies Inc 35 Ipsen SA 35 Isofol Medical AB 36 Johnson & Johnson 36 MacroGenics Inc 37 MD Biosciences GmbH 37 Merck & Co Inc 38 Merck KGaA 38 Novartis AG 39 Oncolys BioPharma Inc 39 Pfizer Inc 40 Teijin Pharma Ltd 40 Osteosarcoma - Drug Profiles 41 12-B80 - Drug Profile 41 3D-QM - Drug Profile 42 3D-QMS - Drug Profile 43 A-1R - Drug Profile 44 ADXS-HER2 - Drug Profile 46 aldoxorubicin hydrochloride - Drug Profile 50 AM-7209 - Drug Profile 68 apatinib - Drug Profile 69 AT-69 - Drug Profile 75 AU-101 - Drug Profile 76 AV-203 - Drug Profile 77 avelumab - Drug Profile 80 axitinib - Drug Profile 91 BMTP-11 - Drug Profile 97 CAB-102 - Drug Profile 99 Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 101 Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile 103 Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 104 Celyvir - Drug Profile 105 cisplatin SR - Drug Profile 106 daunorubicin hydrochloride - Drug Profile 108 dihydroartemisinin - Drug Profile 109 DS-5272 - Drug Profile 110 enoblituzumab - Drug Profile 111 everolimus - Drug Profile 114 glembatumumab vedotin - Drug Profile 126 ipilimumab + nivolumab - Drug Profile 132 irinotecan hydrochloride - Drug Profile 140 JNJ-7107 - Drug Profile 152 lenvatinib mesylate - Drug Profile 155 ligerin - Drug Profile 169 MD-401A - Drug Profile 170 Minnelide - Drug Profile 171 Modufolin - Drug Profile 173 Monoclonal Antibody for Osteosarcoma - Drug Profile 176 Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 177 Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 178 OBP-702 - Drug Profile 180 Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile 181 pazopanib hydrochloride - Drug Profile 182 pembrolizumab - Drug Profile 190 radium Ra 223 dichloride - Drug Profile 251 RSF-101 - Drug Profile 260 SEN-461 - Drug Profile 262 sirolimus albumin-bound - Drug Profile 263 Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile 265 Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 266 Small Molecules to Inhibit MDM2 for Osteosarcoma - Drug Profile 267 taurolidine - Drug Profile 268 Vaccine for Osteosarcoma - Drug Profile 269 VIMO-001 - Drug Profile 270 Osteosarcoma - Dormant Projects 271 Osteosarcoma - Discontinued Products 273 Osteosarcoma - Product Development Milestones 274 Featured News & Press Releases 274 Appendix 282 Methodology 282 Coverage 282 Secondary Research 282 Primary Research 282 Expert Panel Validation 282 Contact Us 282 Disclaimer 283
List of Tables
Number of Products under Development for Osteosarcoma, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Osteosarcoma - Pipeline by Advaxis Inc, H2 2017 Osteosarcoma - Pipeline by Advenchen Laboratories LLC, H2 2017 Osteosarcoma - Pipeline by Amgen Inc, H2 2017 Osteosarcoma - Pipeline by AntiCancer Inc, H2 2017 Osteosarcoma - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017 Osteosarcoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2017 Osteosarcoma - Pipeline by Bayer AG, H2 2017 Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 Osteosarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017 Osteosarcoma - Pipeline by Bristol-Myers Squibb Company, H2 2017 Osteosarcoma - Pipeline by Celldex Therapeutics Inc, H2 2017 Osteosarcoma - Pipeline by Cellmid Ltd, H2 2017 Osteosarcoma - Pipeline by CorMedix Inc, H2 2017 Osteosarcoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2017 Osteosarcoma - Pipeline by Eisai Co Ltd, H2 2017 Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H2 2017 Osteosarcoma - Pipeline by Intezyne Technologies Inc, H2 2017 Osteosarcoma - Pipeline by Ipsen SA, H2 2017 Osteosarcoma - Pipeline by Isofol Medical AB, H2 2017 Osteosarcoma - Pipeline by Johnson & Johnson, H2 2017 Osteosarcoma - Pipeline by MacroGenics Inc, H2 2017 Osteosarcoma - Pipeline by MD Biosciences GmbH, H2 2017 Osteosarcoma - Pipeline by Merck & Co Inc, H2 2017 Osteosarcoma - Pipeline by Merck KGaA, H2 2017 Osteosarcoma - Pipeline by Novartis AG, H2 2017 Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2017 Osteosarcoma - Pipeline by Pfizer Inc, H2 2017 Osteosarcoma - Pipeline by Teijin Pharma Ltd, H2 2017 Osteosarcoma - Dormant Projects, H2 2017 Osteosarcoma - Dormant Projects, H2 2017 (Contd..1), H2 2017 Osteosarcoma - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
